Aller au contenu principal

Radioiodine treatment for pediatric Graves' disease

Egalement disponible en

Graves' disease is a common cause of hyperthyroidism in children and adolescents which excessive amounts of thyroid hormones circulating in the blood. Affected children and adolescents suffer from increased heart beats, warm moist skin, fatigue, weight loss, raised body temperature, eye and other problems. Application of radioactive iodine (radioiodine), surgical removal of the thyroid gland or drugs that interfere with the production of thyroid hormones (antithyroid drugs) are used to treat this disease.
Two relevant trials with 167 patients were identified. The limited data suggest that a gland specific lower dosage of radioiodine treatment is potentially effective for pediatric GD, but a significant higher incidence of hypothyroidism compared with ATD was observed. However, all of the analysed studies were of low quality. No trial evaluated mortality, health related quality of life, economic outcomes or compliance with treatments.

Contexte

Pediatric Graves' disease (GD) is an autoimmune disease in which excessive amounts of thyroid hormones circulate in the blood. Treatments for pediatric GD include antithyroid drugs (ATD), thyroidectomy and radioiodine. Up to date, the optimal therapy remains controversial.

Objectifs

To assess the effects of radioiodine treatment for pediatric GD.

Stratégie de recherche documentaire

Studies were obtained from computerized searches of MEDLINE, EMBASE, The Cochrane Library, China National Infrastructure (CNKI) and paper collections of conferences held in Chinese.

Critères de sélection

Randomised controlled trials, controlled clinical trials and prospective cohort studies comparing the effects of radioiodine with ATD or thyroidectomy with a duration of follow-up at least one year.

Recueil et analyse des données

Two authors independently assessed study quality, extracted data and interviewed authors of all potentially relevant studies by telephone or electronic mail to verify randomization procedures. One author entered data into a data extraction form and another author verified the results of this procedure.

Résultats principaux

Two prospective controlled clinical trials involving 167 patients were included. All of them were of low quality. Radioiodine treatment versus ATD showed benefits in achieving euthyroidism (relative risk (RR) 1.70, 95% confidence interval (CI) 1.29 to 2.24). Radioiodine treatment showed a higher incidence of hypothyroidism compared with ATD (RR 6.46, 95% CI 1.16 to 35.81). No significant differences in modifying Graves' opthalmopathy (worsening or appearance) between radioiodine treatment and ATD (RR 1.30, 95% CI 0.56 to 3.00) were observed. No trial evaluated mortality, health related quality of life, economic outcomes or compliance with treatments.

Conclusions des auteurs

The limited results in Chinese suggest that a gland specific lower dosage of radioiodine treatment is potentially effective for pediatric GD, but a significant higher incidence of hypothyroidism compared with ATD was observed. However, we could not identify a well-designed trial to provide strong evidence for radioiodine in the treatment of pediatric GD. High-quality randomised controlled clinical trials are needed to guide treatment choice.

Citation
Ma C, Kuang A, Xie J, Liu GJ. Radioiodine treatment for pediatric Graves' disease. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD006294. DOI: 10.1002/14651858.CD006294.pub2.

Notre utilisation des cookies

Nous utilisons les cookies nécessaires au fonctionnement de notre site. Nous aimerions également mettre en place des cookies analytiques optionnels pour nous aider à l'améliorer. Nous n'installerons pas de cookies optionnels à moins que vous ne les activiez. L'utilisation de cet outil permettra d'installer un cookie sur votre appareil pour mémoriser vos préférences. Vous pouvez toujours modifier vos préférences en matière de cookies à tout moment en cliquant sur le lien « Paramètres des cookies » en bas de chaque page.
Vous pouvez voir plus d'informations concernant les cookies que nous utilisons sur notre page sur les Cookies

Accepter tout
Configurer